Sumanta K. Pal

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 4%percentile

0.905Author DataRank

Indexed papers

5in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 5 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Prognostic Value of DNA Damage Response Genomic Alterations in Relapsed/Advanced Urothelial Cancer

The Oncologist(2020)10.1634/theoncologist.2019-0851

Top 22%

0.905DataRank

Top 22%21 citations

Petros Grivas, Qi-En Wang, Amir Mortazavi, Hamid Emamekhoo, Sheldon L. Holder +9 more

Papers

Driven by 57 papers — median percentile 0. Top paper: “A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial”.

A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial

The Lancet(2021)10.1016/s0140-6736(21)00152-5

N/A

6.9DataRank · unranked

283 citations

Catherine M. Tangen, Ian M. Thompson, Naomi Balzer-Haas, Daniel J. George, Daniel Y.C. Heng +15 more

Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial

Nature Medicine(2023)10.1038/s41591-023-02568-1

N/A

5.2DataRank · unranked

135 citations

Siamak Daneshmand, Sudeh Izadmehr, Edgar Gonzalez‐Kozlova, Kevin Chan, Sara Lewis +35 more

Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors

Journal of Clinical Oncology(2020)10.1200/jco.20.01652

N/A

3.5DataRank · unranked

138 citations

Rosa Nadal, Daniel M. Girardi, Scot A. Niglio, Lisa Ley, Lisa M. Cordes +30 more

Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma

Journal for ImmunoTherapy of Cancer(2022)10.1136/jitc-2022-005445

N/A

2.7DataRank · unranked

69 citations

Sabina Signoretti, Toni K. Choueiri, David F. McDermott, Robert J. Motzer, Saby George +9 more

Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer

New England Journal of Medicine(2024)10.1056/nejmoa2401497

N/A

2.4DataRank · unranked

64 citations

Catherine M. Tangen, Robert S. Svatek, Siamak Daneshmand, Kamal S. Pohar, Eila C. Skinner +15 more

PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial

Nature Medicine(2024)10.1038/s41591-024-02979-8

N/A

1.8DataRank · unranked

124 citations

M. Suzette Blanchard, Lauren Adkins, Laura Luebbert, Neena A. Leggett, Stephanie N. Shishido +23 more

Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma

JAMA Oncology(2021)10.1001/jamaoncol.2021.3441

N/A

1.6DataRank · unranked

45 citations

Paul Frankel, Amir Mortazavi, Matthew I. Milowsky, Ulka N. Vaishampayan, Mamta Parikh +15 more

Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial

The Lancet(2023)10.1016/s0140-6736(23)00913-3

N/A

1.4DataRank · unranked

49 citations

Catherine M. Tangen, Elisabeth I. Heath, Mark N. Stein, Maxwell V. Meng, Ajjai Alva +14 more

Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-3726

N/A

1.1DataRank · unranked

24 citations

Scot A. Niglio, Amir Mortazavi, Rosa Nadal, Primo Lara, Sumanta K. Pal +30 more

Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810

Journal of Clinical Oncology(2024)10.1200/jco.23.01544

N/A

0.930DataRank · unranked

19 citations

Se Eun Kim, Wayne Harris, Sumanta K. Pal, Michael R. Pins, Jill Kolesar +13 more

Prognostic Value of DNA Damage Response Genomic Alterations in Relapsed/Advanced Urothelial Cancer

The Oncologist(2020)10.1634/theoncologist.2019-0851

Top 22%

0.905DataRank

Top 22%21 citations

Petros Grivas, Qi-En Wang, Amir Mortazavi, Hamid Emamekhoo, Sheldon L. Holder +9 more

A first-in-human phase I study of TAS0728, an oral covalent binding inhibitor of HER2, in patients with advanced solid tumors with HER2 or HER3 aberrations

Investigational New Drugs(2021)10.1007/s10637-021-01104-7

N/A

0.452DataRank · unranked

6 citations

Analía Azaro, Hendrik Tobias Arkenau, Do‐Youn Oh, Matthew D. Galsky, Sumanta K. Pal +6 more

Phase 1b Trial Evaluating Tolerability and Activity of Targeted Fibroblast Growth Factor Receptor Inhibition in Localized Upper Tract Urothelial Carcinoma

The Journal of Urology(2024)10.1097/ju.0000000000003928

N/A

0.411DataRank · unranked

8 citations

Mehrad Adibi, Amishi Y. Shah, Omar Alhalabi, Paul G. Corn, Charles C. Guo +8 more

Dietary Interventions in Cancer Treatment and Response: A Comprehensive Review

Cancers(2022)10.3390/cancers14205149

N/A

0DataRank · unranked

44 citations

Eemon Tizpa, Errol J. Philip, Qianhua Feng, Ziyi Huang, Reeny M. Thomas +4 more

Localized PD-1 Blockade in a Mouse Model of Renal Cell Carcinoma

Frontiers in Drug Delivery(2022)10.3389/fddev.2022.838458

N/A

0DataRank · unranked

6 citations

Nevil Abraham, Ketki Y. Velankar, Nathan R. Schueller, Errol J. Philip, Yasmeen Jaber +5 more

EVEREST: Everolimus for renal cancer ensuing surgical therapy—A phase III study (SWOG S0931, NCT01120249).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.17_suppl.lba4500

N/A

0DataRank · unranked

39 citations

Catherine M. Tangen, Elisabeth I. Heath, Mark N. Stein, Maxwell V. Meng, Ajjai Alva +15 more

SWOG S1931 (PROBE): Phase III randomized trial of immune checkpoint inhibitor (ICI) combination regimen with or without cytoreductive nephrectomy (CN) in advanced renal cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.tps402

N/A

0DataRank · unranked

17 citations

Catherine M. Tangen, Abhishek Tripathi, Brian Shuch, Sumanta K. Pal, Pedro C. Barata +9 more

The association of FDG PET/CT and NaF PET/CT with survival outcomes in patients (pts) with metastatic genitourinary malignancies (mGU) treated with cabozantinib + nivolumab +/- ipilimumab (CaboNivo +/- Ipi).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.452

N/A

0DataRank · unranked

0 citations

Katherine Lei, Nicholas Peter Verdini, Jeffrey Lin, Andy Vega, Scot A. Niglio +13 more

Melanoma and microbiota: Current understanding and future directions

Cancer Cell(2023)10.1016/j.ccell.2023.12.003

N/A

0DataRank · unranked

82 citations

Tanisha Jackson, Laura Mählmann, Christina K. Baumgartner, Martin J. Blaser, Allyson L. Byrd +26 more

Metastatic renal cell carcinoma to the pancreas and other sites—a multicenter retrospective study

EClinicalMedicine(2023)10.1016/j.eclinm.2023.102018

N/A

0DataRank · unranked

26 citations

Junxiao Hu, Benoit Beuselinck, Justine Panian, Nicole Weise, Nazlı Dizman +23 more

A Practical Guide to Relugolix: Early Experience With Oral Androgen Deprivation Therapy

The Oncologist(2023)10.1093/oncolo/oyad036

N/A

0DataRank · unranked

17 citations

Oren Wei, Ni‐Chun Tsai, Joycelynne Palmer, Sumanta K. Pal, Yung Lyou +2 more

Antitumor immunity as the basis for durable disease-free treatment-free survival in patients with metastatic urothelial cancer

Journal for ImmunoTherapy of Cancer(2023)10.1136/jitc-2023-007613

N/A

0DataRank · unranked

15 citations

Sumanta K. Pal, Seunghee Kim‐Schulze, Huan Wang, Rebecca F. Halperin, Andrew Uzilov +12 more

SWOG S1011: A phase III surgical trial to evaluate the benefit of a standard versus an extended lymphadenectomy performed at time of radical cystectomy for muscle invasive urothelial cancer.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.4508

N/A

0DataRank · unranked

39 citations

Catherine M. Tangen, Robert S. Svatek, Siamak Daneshmand, Kamal S. Pohar, Eila C. Skinner +15 more

Adjuvant everolimus in patients (Pts) with localized non-clear cell renal cell carcinoma (RCC): Subgroup analysis from the Everest trial (SWOG S0931).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.4546

N/A

0DataRank · unranked

2 citations

Catherine M. Tangen, Christopher W. Ryan, Ulka N. Vaishampayan, Brian Shuch, Pedro C. Barata +7 more

Pathologic concordance rate and outcomes by histologic subtype in advanced papillary renal cell (pRCC) carcinoma: An analysis from the SWOG S1500 (PAPMET) trial.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.4562

N/A

0DataRank · unranked

1 citations

Catherine M. Tangen, Xiaochen Li, Maria Tretiakova, Peter A. Humphrey, Adebowale Adeniran +9 more

Supplementary Figure from Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy

(2023)10.1158/1078-0432.22486571

Top 100%

0DataRank

Top 100%0 citations

Scot A. Niglio, Amir Mortazavi, Rosa Nadal, Primo N. Lara, Sumanta K. Pal +30 more

Supplementary Figure from Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy

Figshare(2023)10.1158/1078-0432.22486556.v1

Top 100%

0DataRank

Top 100%0 citations

Scot A. Niglio, Amir Mortazavi, Rosa Nadal, Primo N. Lara, Sumanta K. Pal +30 more

Data from Antiangiogenic and Antimetastatic Activity of JAK Inhibitor AZD1480

(2023)10.1158/0008-5472.c.6502904.v1

N/A

0DataRank · unranked

0 citations

Andreas Herrmann, Karen L. Reckamp, Wang Zhang, Sumanta K. Pal, Michael Hedvat +12 more

Data from Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer

(2023)10.1158/1078-0432.c.6529986

N/A

0DataRank · unranked

0 citations

Tiziano Pramparo, Amir Mortazavi, Scot A. Niglio, Joseph D. Schonhoft, Adam Jendrisak +26 more

Data from Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma

(2023)10.1158/1078-0432.c.6529871

N/A

0DataRank · unranked

0 citations

Sabina Signoretti, Toni K. Choueiri, David F. McDermott, Robert J. Motzer, Abdallah Flaifel +19 more

Data from Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy

(2023)10.1158/1078-0432.c.6532346.v1

Top 100%

0DataRank

Top 100%0 citations

Scot A. Niglio, Amir Mortazavi, Rosa Nadal, Primo N. Lara, Sumanta K. Pal +30 more

Final results from a phase 1 trial and expansion cohorts of cabozantinib and nivolumab alone or with ipilimumab for advanced/metastatic genitourinary tumors

Research Square(2023)10.21203/rs.3.rs-2924051/v1

N/A

0DataRank · unranked

0 citations

Scot A. Niglio, Rosa Nadal, Andre R. Kydd, Nicholas I. Simon, Lisa Ley +36 more

FDG PET/CT and NaF PET/CT imaging quantification of osseous metastatic lesions in patients with metastatic genitourinary (mGU) cancer and their association with survival outcomes.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.e16573

N/A

0DataRank · unranked

0 citations

Nicholas I. Simon, Elias Chandran, Katherine Lei, Nicholas Peter Verdini, Jeffrey Lin +15 more

Association of 18F-FDG PET characteristics and survival outcomes using whole body tumor analysis in patients (pts) with metastatic genitourinary (GU) malignancies.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.4600

N/A

0DataRank · unranked

0 citations

Rod Carlo Columbres, Elias Chandran, Scot A. Niglio, Lisa M. Cordes, Lisa Ley +9 more

The association of sociodemographic variables with smoking prevalence in patients enrolled on clinical trials.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.e13595

Top 100%

0DataRank

Top 100%0 citations

Riha Vaidya, Cathee Till, Kimlin Ashing, Graham Warren, Dawn L. Hershman +13 more

Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes

Cancer Cell(2024)10.1016/j.ccell.2024.03.002

N/A

0DataRank · unranked

46 citations

Chris Labaki, Tejas Jammihal, Wanling Xie, Maxine Sun, Valisha Shah +19 more

Targeting STAT3 in tumor-associated antigen-presenting cells as a strategy for kidney and bladder cancer immunotherapy

Frontiers in Immunology(2024)10.3389/fimmu.2023.1274781

N/A

0DataRank · unranked

18 citations

Wilson S. Tang, Dongfang Wang, Damian Kaniowski, Elaine Kang, Nazlı Dizman +11 more

Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial

European Urology(2024)10.1016/j.eururo.2024.05.012

N/A

0DataRank · unranked

8 citations

Catherine M. Tangen, Elisabeth I. Heath, Shuchi Gulati, Mark N. Stein, Maxwell V. Meng +16 more

Pathological concordance rate and outcomes by subtype in advanced papillary renal cell carcinoma

British Journal of Urology(2024)10.1111/bju.16403

N/A

0DataRank · unranked

1 citations

Catherine M. Tangen, Melissa Plets, Xiaochen Li, Maria Tretiakova, Peter A. Humphrey +11 more

Smoking prevalence and association with sociodemographic variables in cancer clinical trial participants

Cancer(2024)10.1002/cncr.35560

N/A

0DataRank · unranked

2 citations

Cathee Till, Riha Vaidya, Kimlin Ashing, Graham Warren, Virginia Sun +11 more

Patterns of chemotherapy administration in bladder preservation therapy (BPT) for muscle-invasive bladder cancer (MIBC).

Carolina Digital Repository (University of North Carolina at Chapel Hill)(2024)10.17615/7y09-8d51

N/A

0DataRank · unranked

0 citations

Evan Y. Yu, Lauren C. Harshman, Nielsen, Matthew Edward, Yu‐Ning Wong, Andrew Z. Wang +14 more

End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer

Journal of Clinical Oncology(2025)10.1200/jco-25-01608

N/A

0DataRank · unranked

16 citations

Matthew D. Galsky, Nazlı Dizman, David H. Aggen, Neeraj Agarwal, Hikmat Al‐Ahmadie +39 more

Comprehensive tumor-immune profiling reveals mediators of paradoxical immune sensitivity in sarcomatoid renal cell carcinoma

Cancer Cell(2025)10.1016/j.ccell.2025.07.010

N/A

0DataRank · unranked

14 citations

Adil Khan, Wilhelm M. Aubrecht, Gavin C Twoey, Jacky Chow, Kristopher Attwood +26 more

Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-2063

N/A

0DataRank · unranked

243 citations

Sabina Signoretti, Toni K. Choueiri, David F. McDermott, Robert J. Motzer, Abdallah Flaifel +19 more

Immune Modulation During Treatment with Enzalutamide Alone or with Radium-223 in Patients with Castration Resistant Prostate Cancer

Cancers(2025)10.3390/cancers17101730

N/A

0DataRank · unranked

0 citations

Diane M. Da Silva, Zhang‐Xu Liu, Shivani Kandukuri, Denice Tsao‐Wei, Anishka D'souza +8 more

Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-2891

N/A

0DataRank · unranked

48 citations

Tiziano Pramparo, Amir Mortazavi, Scot A. Niglio, Joseph D. Schonhoft, Adam Jendrisak +26 more

Summary From the First Kidney Cancer Research Summit, September 12–13, 2019: A Focus on Translational Research

JNCI Journal of the National Cancer Institute(2020)10.1093/jnci/djaa064

N/A

0DataRank · unranked

40 citations

Michael B. Atkins, Ziad Bakouny, Maria I. Carlo, Charles G. Drake, Eric Jonasch +15 more

Physical activity and risk of bladder cancer among postmenopausal women

International Journal of Cancer(2020)10.1002/ijc.33042

N/A

0DataRank · unranked

7 citations

Michael Hendryx, Pengcheng Xun, Ka He, Aladdin H. Shadyab, Dorothy S. Lane +6 more

Strategies to Improve Participation of Older Adults in Cancer Research

Journal of Clinical Medicine(2020)10.3390/jcm9051571

N/A

0DataRank · unranked

30 citations

Eutiquio Gutierrez, Abhay Tiwari, Simran Padam, Daneng Li, William Dale +15 more

Co-stimulatory and co-inhibitory Immune Markers in Solid Tumors With MET Alterations

Future Science OA(2020)10.2144/fsoa-2020-0159

N/A

0DataRank · unranked

2 citations

Jasmine A. McQuerry, Isa Mambetsariev, Rebecca Pharaon, Susan E. Yost, Jeremy Fricke +14 more

Ipilimumab challenge/re-challenge in metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors treated with cabozantinib+nivolumab (CaboNivo) or cabozantinib+nivolumab+ipilimumab (CaboNivoIpi).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.5039

N/A

0DataRank · unranked

3 citations

Daniel M. Girardi, Amir Mortazavi, Primo N. Lara, Sumanta K. Pal, Biren Saraiya +15 more

Phase I expansion study of cabozantinib plus nivolumab (CaboNivo) in metastatic urothelial carcinoma (mUC) patients (pts) with progressive disease following immune checkpoint inhibitor (ICI) therapy.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.5037

N/A

0DataRank · unranked

2 citations

Scot A. Niglio, Amir Mortazavi, Primo Lara, Sumanta K. Pal, Biren Saraiya +15 more

COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials

Nature Reviews Clinical Oncology(2021)10.1038/s41571-021-00487-z

N/A

0DataRank · unranked

140 citations

Justin F. Gainor, Aparna Hegde, Alison M. Schram, Giuseppe Curigliano, Sumanta K. Pal +19 more

Treatment Pattern and Outcomes with Systemic Therapy in Men with Metastatic Prostate Cancer in the Real-World Patients in the United States

Cancers(2021)10.3390/cancers13194951

N/A

0DataRank · unranked

51 citations

Jennifer A. Sinnott, Benjamin Haaland, Nicolas Sayegh, Taylor Ryan McFarland, Nishita Tripathi +8 more

Sunitinib versus cabozantinib, crizotinib or savolitinib in metastatic papillary renal cell carcinoma (pRCC): Results from the randomized phase II SWOG 1500 study.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.270

N/A

0DataRank · unranked

9 citations

Catherine M. Tangen, Ian M. Thompson, Naomi B. Haas, Daniel J. George, Daniel Yick Chin Heng +15 more

Final results from a phase I trial and expansion cohorts of cabozantinib and nivolumab (CaboNivo) alone or with ipilimumab (CaboNivoIpi) for metastatic genitourinary tumors.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.3

N/A

0DataRank · unranked

9 citations

Daniel M. Girardi, Scot A. Niglio, Rosa Maria Nadal, Lisa M. Cordes, Seth M. Steinberg +15 more

A randomized phase II study comparing cisplatin and gemcitabine with or without berzosertib in patients with advanced urothelial carcinoma.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.4507

N/A

0DataRank · unranked

1 citations

Amir Mortazavi, Matthew I. Milowsky, Ulka N. Vaishampayan, Mamta Parikh, Yung Lyou +15 more

Sumanta K. Pal

Indexed papers

Top data-sharing exemplar

Papers